News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Loxo Oncology Initiates Phase 1 Trial Of Loxo 101, A Selective TRK Inhibitor


5/1/2014 2:11:17 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STAMFORD, Conn.--(BUSINESS WIRE)--Loxo Oncology, Inc., a biopharmaceutical company focused on targeted cancer therapies for genetically-defined populations, announced today that it has initiated a Phase 1 Study for its lead compound, LOXO-101, a potent and selective inhibitor of the tropomyosin kinase (TRK) family of receptors. The Phase 1 study will evaluate the safety, pharmacokinetics and pharmacodynamics of escalating doses of LOXO-101 and, in a second stage, will also provide a preliminary assessment of anti-tumor activity in cancer patients preselected to have an alteration in genes affecting the TRKA, TRKB or TRKC proteins.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES